Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q1 FY2026 net change in cash was -$13.5M, compared with $27.8M a year earlier. Trailing-twelve-month net change in cash was -$19.32M.

Context

  • Net change in cash amounted to 181.0% of revenue in FY2025, down 2.1 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$13.5M or moves back toward the trailing-twelve-month quarterly average of -$4.83M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.5M+10.0% QoQ
Last fiscal yearDec 2025
$21.97M+271.4% YoY
LTMMar 2026
-$19.32M-224.2% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-148.6%——
1 year+271.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
21.97M USD
Year-over-year change
+271.4%

Net Change in Cash vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -224.2% is the 10th highest of 11, against a peer median of +195.3%.
  • Net change in cash amounts to 115.6% of revenue for PRLD, versus a peer median of 126.9%.
PRLD Competitors
Net Change in Cash for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$100M USD-769.9%+42.0%169491.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$27.89M USD+253.0%—98.8%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$27.12M USD+568.0%+19.1%12051.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$25.29M USD+542.2%-17.4%36.5%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$19.32M USD-224.2%—115.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$17.36M USD-13.1%-72.2%155.0%
IVAInventiva S.A.FY2025€14.17M EUR-79.7%+326.2%316.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$11.75M USD+1066.8%+102.1%—
IMRXImmuneering CorporationLTM Mar 2026$11.46M USD+137.7%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$10.02M USD+301.3%+8.1%30.6%
PYXSPyxis Oncology, Inc.LTM Mar 2026$6.99M USD-54.0%-65.1%50.5%
Peer median (excluding PRLD) —+195.3%+13.6%126.9%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Depreciation & Amortization915K1.32M1.17M1.77M1.34M
Deferred Income Tax00000
Stock-Based Compensation20.93M25.14M25.62M21.35M11.91M
Change in Working Capital3.63M932K(10.48M)4.22M28.41M
Accounts Receivables00000
Inventory00000
Accounts Payables3.9M(347K)(2.27M)3.31M(3.92M)
Other Working Capital(278K)1.28M(8.21M)911K32.33M
Other Non-Cash Items2.69M4.31M(1.54M)(3.05M)1.53M
Operating Cash Flow(83.53M)(83.73M)(107.06M)(102.89M)(56.3M)
Capital Expenditures(2.32M)(3.02M)(3.51M)(764K)(67K)
Acquisitions (Net)00000
Purchases of Investments(261.48M)(119.22M)(221.63M)(52.69M)(100.87M)
Sales of Investments0203.93M190.5M143.65M154.39M
Other Investing Activities00000
Investing Cash Flow(263.8M)81.69M(34.65M)90.19M53.46M
Debt Repayment000(395K)(208K)
Common Stock Issued161.42M815K135.73M329K25.04M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.47M0664K(54K)(17K)
Financing Cash Flow164.9M815K136.4M(120K)24.82M
Effect of Forex Changes00000
Net Change in Cash(182.44M)(1.22M)(5.31M)(12.82M)21.97M
Free Cash Flow(85.85M)(86.75M)(110.58M)(103.65M)(56.37M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.